A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) ...

Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the ...

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

A mutation in the KRAS gene can lead to uncontrollable cell growth and the development of cancer. Having this mutation can significantly influence the treatment and outlook of people with colon ...

Discover Cardiff Oncology's promising results with Onvansertib for RAS-mutated colorectal cancer, potentially leading to ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

The ANCC’s global credential recognises organisations that create a supportive and empowering work environment for nurses.

The candidate, IBI363, is designed to block the PD-1/PD-L1 pathway, unleashing similar effects ... seeing responses in patients with and without KRAS/NRAS exon 2/3/4 mutations, and safety aligning ...

Martyn Irvine has said he is very much looking forward to getting stuck into his new role with Cycling Ireland following ...